Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis

Status:
Completed

Trial end date:
0000-00-00

Target enrollment:

Participant gender:

The purpose of this open-label study is to evaluate the long-term safety and efficacy of ABP 501.

Phase 3

Amgen

Adalimumab